Cyclacel Pharmaceuticals to Present New Clinical Data From Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium
09. Oktober 2024 09:15 ET
|
Cyclacel
Initial safety and efficacy data from fadraciclib monotherapy in patients with advanced solid tumors preselected for CDKN2A and/or CDKN2B abnormalities
Cyclacel Pharmaceuticals Announces Completion of Enrollment in the Biomarker-Enriched Patient Cohort of Its Phase 2 Study
25. September 2024 09:15 ET
|
Cyclacel
Cyclacel announces completion of enrollment in the biomarker-enriched
cohort of its Phase 2 study
- Patients are preselected for C
Cyclacel Pharmaceuticals Reports First Quarter Financial Results and Provides Business Update
14. Mai 2024 16:05 ET
|
Cyclacel
- New Clinical Data to be Presented at ASCO Annual Meeting Highlighting Potential Precision Medicine Strategy with Oral Fadraciclib -- First Patients Enrolled in Oral Fadraciclib Phase 2 Proof of...
Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
19. März 2024 16:05 ET
|
Cyclacel
– On Track to Start Oral Fadraciclib Phase 2 Proof of Concept in 1H 2024 – – Expect to Report Final Data from Fadraciclib 065-101 Dose Escalation – – Oral Plogosertib Preclinical Data Support...
Cyclacel Pharmaceuticals Reports Fadraciclib Phase 1 Data Suggesting Efficacy Against Tumors With CDKN2A, CDKN2B and MTAP Deletions
18. Dezember 2023 09:00 ET
|
Cyclacel
- Patient Pharmacodynamic Data Show Decrease in CDKN2A, CDKN2B, and PRMT5 Protein Levels - - A Squamous Non-Small Cell Lung Cancer Patient with CDKN2B Deletion Achieved Marked Tumor Shrinkage...
Advanced Dermatology and Cosmetic Surgery Provides Breast Cancer Patients and Survivors with Free Skin Cancer Screenings for Breast Cancer Awareness Month
20. September 2022 09:00 ET
|
Advanced Dermatology and Cosmetic Surgery
MAITLAND, Fla., Sept. 20, 2022 (GLOBE NEWSWIRE) -- In honor of Breast Cancer Awareness Month, Advanced Dermatology and Cosmetic Surgery announces it will offer complimentary skin cancer screenings...